Regenerative Medicine Market to be Worth $180.87 Billion by 2030: Grand View Research, Inc.

News provided by

Feb 14, 2023, 03:51 ET

SAN FRANCISCO, Feb. 14, 2023 /PRNewswire/ -- The global regenerative medicine market size is expected to reach USD 180.87 billion by 2030 expanding at a CAGR of 15.7% from 2023 to 2030, according to a new report by Grand View Research, Inc., The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Key Industry Insights & Findings from the report:

The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks.
North America dominated the market in 2022 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
By therapeutic category, the oncology segment dominated the segment in 2022 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth.

Read 180-page full market research report, "Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research.

Regenerative Medicine Market Growth & Trends

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA, This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson's disease treatment. This approval was expected to expand the company's offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Segmentation

Grand View Research has segmented the regenerative medicine market report based on product, therapeutic category, and region

Regenerative Medicine Market - Product Outlook (Revenue, USD Million, 2018 - 2030)

Therapeutics

Primary cell-based therapeutics

Dermatology
Musculoskeletal
Surgical
Dental
Others

Stem Cell & Progenitor Cell-based therapeutics

Autologous
Allogenic
Others

Cell-based Immunotherapies
Gene Therapies

Tools
Banks
Services

Regenerative Medicine Market - Therapeutic Category Outlook (Revenue, USD Million, 2018 - 2030)

Dermatology
Musculoskeletal
Immunology & Inflammation
Oncology
Cardiovascular
Ophthalmology
Others

Regenerative Medicine Market - Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.
Canada

Europe

Germany
U.K.
France
Italy
Spain
Denmark
Sweden
Norway

Asia Pacific

China
India
Japan
South Korea
Australia
Thailand

Latin America

Brazil
Mexico
Argentina

Middle East & Africa

South Africa
Saudi Arabia
UAE
Kuwait

List of Key Players of Regenerative Medicine Market

AstraZeneca plc
F. Hoffmann-La Roche Ltd.
Integra Lifesciences Corp.
Astellas Pharma, Inc.
Cook Biotech, Inc.
Bayer AG
Pfizer, Inc.
Merck KGaA
Abbott
Vericel Corp.
Novartis AG
GlaxoSmithKline (GSK)
Baxter International, Inc.
Boehringer Ingelheim
Amgen Inc.
Cesca Therapeutics, Inc.
U.S. Stem Cell, Inc.
Bristol-Myers Squibb
Eli Lilly and Company
NuVasive, Inc.
Organogenesis, Inc.
MiMedx Group, Inc.
Takara Bio, Inc.
Osiris Therapeutics, Inc.
Corline Biomedical AB

Check out more related studies published by Grand View Research:

Induced Pluripotent Stem Cells Production Market - The global induced pluripotent stem cells production market size is estimated to reach USD 2.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.2% from 2022 to 2030. The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market. Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth. In addition, the prevalence of chronic disorders is also driving the growth of the induced pluripotent stem cells production market, as conditions like heart disease, stroke, diabetes, and many more can be treated by utilizing iPSCs-mediated therapy. For example, according to the International Diabetes Federation (IDF), 537 million people are already living with diabetes in 2021.
Microcarriers Market - The global microcarriers market size is estimated to reach USD 3.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.6% from 2022 to 2030. The growth of the market is driven by the rising demand of cell-cultured products, the growing burden of diseases worldwide, constant investments for intensive R&D activities to identify and develop new treatments for rare disorders, and the continuous developments in technologies employed in advanced research such as cell-biology.
Biopreservation Market - The global bio preservation market size is projected to reach USD 16.61 billion by 2030, registering a CAGR of 28.9% from 2022 to 2030, according to a new report by Grand View Research, Inc. The extensive use of preservation in hospitals and labs, rising funding assistance from government and private partners in healthcare, and an upsurge in research and development are fueling the industry growth.

Browse through Grand View Research's Biotechnology Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Grand View Compass | Astra ESG Solutions
Follow Us: LinkedIn | Twitter